Suchergebnisse - "Bellam, Naresh"

PubPharm (26)

1

Emergence of TP53 mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine

enthalten in: Haematologica | 2024

von Gangat, N. | Bellam, N. | Reichard, K. | +1

2

Paclitaxel-Induced Palmar-Plantar Erythrodysesthesia

enthalten in: Cureus | 2020

von Wahab, A. | Khakwani, M. | Ehsan, H. | +1

3

Zinc-induced copper deficiency, sideroblastic anemia, and neutropenia : A perplexing facet of zinc excess

enthalten in: Clinical case reports | 2020

von Wahab, A. | Mushtaq, K. | Borak, S. | +1

4

Zinc‐induced copper deficiency, sideroblastic anemia, and neutropenia : A perplexing facet of zinc excess

enthalten in: Clinical Case Reports | 2020

von Wahab, A. | Mushtaq, K. | Borak, S. | +1

5

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Horwitz, S. | O'Connor, O. | Pro, B. | +129

CommentIn: Lancet. 2019 Jan 19;393(10168):201-202. - PMID 30663580

6

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

enthalten in: Investigational new drugs | 2014

von Gopal, A. | Tarantolo, S. | Bellam, N. | +7

7

Non-Hodgkin's lymphomas, version 2.2014

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2014

von Zelenetz, A. | Gordon, L. | Wierda, W. | +31

8

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

enthalten in: Investigational new drugs | 2014

von Gopal, A. | Tarantolo, S. | Bellam, N. | +7

9

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

enthalten in: Investigational new drugs | 2014

von Gopal, A. | Tarantolo, S. | Bellam, N. | +7

10

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

enthalten in: Investigational new drugs | 2014

von Gopal, A. | Tarantolo, S. | Bellam, N. | +7